Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency

Three patients with renal insufficiency requiring hemodialysis were treated with carboplatin at 100 mg/m2 in combination with etoposide for advanced germ-cell tumor (GCT, two cases) or Adriamycin + vinblastine for a transitional-cell carcinoma of the ureter (one case). Hemodialysis was performed 24...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1990-01, Vol.27 (3), p.234-238
Main Authors: MOTZER, R. J, NIEDZWIECKI, D, ISAACS, M, MENENDEZ-BOTET, C, TONG, W. P, FLOMBAUM, C, SCHER, H. I, BOSL, G. J
Format: Article
Language:English
Subjects:
Adult
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Carboplatin - administration & dosage
Carboplatin - pharmacokinetics
Carcinoma, Transitional Cell - drug therapy
Chemotherapy
Humans
Kidney Failure, Chronic - metabolism
Male
Medical sciences
Neoplasms, Germ Cell and Embryonal - drug therapy
Pharmacology. Drug treatments
Renal Dialysis
Ureteral Neoplasms - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Three patients with renal insufficiency requiring hemodialysis were treated with carboplatin at 100 mg/m2 in combination with etoposide for advanced germ-cell tumor (GCT, two cases) or Adriamycin + vinblastine for a transitional-cell carcinoma of the ureter (one case). Hemodialysis was performed 24 h after the administration of carboplatin. Both patients with GCT achieved a complete response, and the patient with transitional-cell carcinoma of the ureter was inevaluable for response but his disease has not progressed. The dose of carboplatin was increased in one patient as renal function improved on therapy. In two patients, the pharmacokinetics of carboplatin were determined; the pre-dialysis half-lives, AUC, and total body clearances of free carboplatin-derived platinum were estimated to be 32 and 18.3 h, 4.93 and 6.17 mg ml-1 min, and 18.2 and 18.7 ml/min, respectively. The dialysis elimination half-lives (t1/2 beta) of 2 and 3 h, respectively, for these two patients were markedly lower than the predialysis values, indicating that carboplatin was dialyzed. In summary, carboplatin can be given to patients with severe renal insufficiency. Adequate AUCs were achieved and dialysis limited systemic exposure to free carboplatin.
ISSN:0344-5704
1432-0843
DOI:10.1007/BF00685719